HOMOLOGOUS RECOMBINATION DEFICIENCY
Clinical trials for HOMOLOGOUS RECOMBINATION DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new HOMOLOGOUS RECOMBINATION DEFICIENCY trials appear
Sign up with your email to follow new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Hormone boost plus chemo aims to shrink hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether a high dose of testosterone combined with the chemotherapy drug carboplatin can help men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 30 men with a genetic defect called homologous recombi…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE2 • Sponsor: St Vincent's Hospital, Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC